Netmeds Acquires JustDoc.com to Strengthen Doctor Network

IMT News Desk
IMT News Desk
· 2 min read
Netmeds

Netmeds.com, an online pharmacy announced that the company has bolstered its expertise in the online healthcare space by acquiring telemedicine portal JustDoc.com in a cash and stock transaction.
Founded in 2015, JustDoc.com is a robust online consulting portal, which connects patients with reputed
doctors via their technology platform. JustDoc has served thousands of patients throughout India through their website and app.
Speaking about the acquisition, Founder & CEO of Netmeds, Pradeep Dadha said, “In addition to prescription medicine and OTC products, we also offer customers ‘The Vault’, our proprietary Electronic Health Records storage app. The acquisition of JustDoc brings an extensive and experienced physicians’ network, which will be the perfect addition to our present range of products and services at this stage in our growth plan.”
Netmeds.com provides prescription medicine and healthcare products to more than 3,000,000 patients across India, serving over 19,000+ pin codes. The company has seen double-digit growth rates month-on-month since inception.
Dadha sees this acquisition as an extension of the company’s quest to provide a robust panoply of
health-related products and services. “Netmeds will continue to expand the scope of its offerings to include diagnostics, lifestyle-related consulting and a patient ‘peer-to-peer’ social network channel. Adding end-to-end video consultation workflows can make the whole process of providing high quality and affordable healthcare services far more efficient.”
Netmeds diagnostics will give customers the added benefits of expert advice from medical professionals
delivered to them using cutting-edge technology with the aim to improving healthcare outcomes.
An initiative by IIT graduates Jugal Anchalia and Abhishek Kumar, JustDoc.com was launched with the intention of providing video medical consultation anywhere in the country by connecting users to the best possible doctors at minimum cost. Netmeds will leverage the combined strengths of both companies by fully absorbing the JustDoc team. The JustDoc technology will be integrated with Netmeds.com and the new offering with roll out shortly.

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk